AbbVie announced on Friday that the USA Food and Drug Administration approved its drug for the treatment of complicated intra-abdominal infections, including those caused by resistant bacteria. AbbVie and its co-developer, Pfizer, received approval for the drug Emblaveo to be used in conjunction with antibiotics for treating patients aged 18 and older with such infections. In the USA, approximately 3.5 million people are affected by intra-abdominal infections (IAIs) each year, which can lead to symptoms such as abdominal pain, fever, nausea, and vomiting. Emblaveo was approved in Europe in April last year and is expected to be launched in the USA in the third quarter of 2025. AbbVie holds the commercialization rights for this therapy in the USA and Canada, while Pfizer is responsible for its commercialization in all other regions.